Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma
AbstractBackgroundSarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia.ObjectiveTo evaluate the prognostic impact of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC).Patients and MethodsSixty-nine patients were evaluated retrospectively. The skeletal muscle index (SMI) was calculated based on computed tomography images obtained before the initiation (pre-treatment SMI) and after two cycles of sunitinib treatment (post-treatment SMI). The change in SMM was evaluated based on the value of ΔSMI,...
Source: Targeted Oncology - October 16, 2018 Category: Cancer & Oncology Source Type: research

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy
ConclusionCytoreductive nephrectomy seems to result in a survival benefit in both clear cell and non-clear cell histology, while no survival advantage was found in patients with specific clinical features. Despite a high level of heterogeneity, our results highlight the importance of a good selection of patients to whom a primary surgical approach could be proposed. (Source: Targeted Oncology)
Source: Targeted Oncology - October 15, 2018 Category: Cancer & Oncology Source Type: research

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
AbstractBackgroundA consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO).ObjectiveSince serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low baseline serum sodium concentration ( ≤ 135 mEq/L) and clinical outcomes of patients with metastatic NSCLC treated with IO.Patients and MethodsWe included metastatic NSCLC patients treated with checkpoint inhibitors in our department from April 2013 to April 2018 with available baseline serum sodi...
Source: Targeted Oncology - October 10, 2018 Category: Cancer & Oncology Source Type: research

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
AbstractBackgroundNon-small cell lung cancer (NSCLC) has a 5-year survival of 5 –16%. Epidermal growth factor receptor (EGFR) mutations, in most cases, confer sensitivity toEGFR tyrosine kinase inhibitor (TKI) therapy. Nonetheless, it is still unclear why clinical outcomes vary among patients with identicalEGFR mutations. The amplification of theEGFR gene (EGFRamp) may play a significant role.ObjectiveCompare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib withEGFR mutations (L858R or exo...
Source: Targeted Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
AbstractOncogenic somatic chromosomal rearrangements involving theNTRK1,NTRK2 orNTRK3 genes (NTRK gene fusions) occur in up to 1% of all solid tumors, and have been reported across a wide range of tumor types. The fusion proteins encoded by such rearranged sequences have constitutively activated TRK tyrosine kinase domains, providing novel therapeutic anticancer targets. The potential clinical effectiveness of TRK inhibition in patients with tumors harboringNTRK gene fusions is being assessed in phase I and II trials of TRK inhibitors, such as larotrectinib and entrectinib. Clinical trial results have demonstrated that lar...
Source: Targeted Oncology - October 2, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Enhanced digital features were retrospectively added to this article. (Source: Targeted Oncology)
Source: Targeted Oncology - October 2, 2018 Category: Cancer & Oncology Source Type: research

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
AbstractOncogenic somatic chromosomal rearrangements involving theNTRK1,NTRK2 orNTRK3 genes (NTRK gene fusions) occur in up to 1% of all solid tumors, and have been reported across a wide range of tumor types. The fusion proteins encoded by such rearranged sequences have constitutively activated TRK tyrosine kinase domains, providing novel therapeutic anticancer targets. The potential clinical effectiveness of TRK inhibition in patients with tumors harboringNTRK gene fusions is being assessed in phase I and II trials of TRK inhibitors, such as larotrectinib and entrectinib. Clinical trial results have demonstrated that lar...
Source: Targeted Oncology - October 2, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Enhanced digital features were retrospectively added to this article. (Source: Targeted Oncology)
Source: Targeted Oncology - October 2, 2018 Category: Cancer & Oncology Source Type: research

Tumor Type-Agnostic Treatment and the Future of Cancer Therapy
(Source: Targeted Oncology)
Source: Targeted Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
ConclusionsTreatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC. (Source: Targeted Oncology)
Source: Targeted Oncology - September 28, 2018 Category: Cancer & Oncology Source Type: research

Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane
ConclusionsOur results show that everolimus toxicity is related to everolimus Ctrough. No relation was observed between everolimus exposure and treatment effectiveness. An early FDG-PET can identify patients at high risk of nonresponse. These results warrant further validation.Clinicaltrials.gov identifier: NCT01948960. (Source: Targeted Oncology)
Source: Targeted Oncology - September 27, 2018 Category: Cancer & Oncology Source Type: research

Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study
The objective of this study was to assess cases of rapid disease progression/immediate development of progressive disease (immediate PD) in patients with pretreated metastatic renal cell carcinoma (mRCC) treated with nivolumab.Patients and MethodsForty patients were retrospectively evaluated. Immediate PD within the initial two cycles of nivolumab therapy was clinically or objectively diagnosed. Clinical diagnosis was defined as an acceleration of symptoms directly caused by tumor growth or systematic worsening of the general condition, such as cachexia. Objective diagnosis was based on imaging evaluation using the Respons...
Source: Targeted Oncology - September 19, 2018 Category: Cancer & Oncology Source Type: research

Targeting Toll-Like Receptors for Cancer Therapy
AbstractThe immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors (TLRs) are critically involved in innate immunity, serving as pattern recognition receptors whose stimulation leads to additional innate and adaptive immune responses. Malignant cells exploit the natural immunomodulatory functions of TLRs, expressed mainly by infiltrating immune cells but also aberrantly by tumor cells, to foster their survival, invasion, and evasion of anti-tumor immune responses. An extensive body of research has demonstrated...
Source: Targeted Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review
AbstractBackgroundOncogenic fusion genes consisting of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) can be detected in 5 –7% of lung adenocarcinoma cases. The prevalence of ALK rearrangement in non-adenocarcinoma, non-small cell lung cancers (NA-NSCLC) is currently unknown. In addition, the efficacy of crizotinib in these patients has not been well established.ObjectivesThe aim of this study was to investigate the prevalence of ALK rearrangement in NA-NSCLC patients and the therapeutic efficacy of crizotinib in these patients.MethodsWe included NA-NSCLC patients who wer...
Source: Targeted Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer
ConclusionsOur study showed a lack of complete concordance between the CHAARTED and LATITUDE classifications. The analysis confirmed the role of these prognostic scores to stratify de novo mHSPC patients in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - August 30, 2018 Category: Cancer & Oncology Source Type: research

Targeted Therapies in the Treatment of Sarcomas
AbstractAbout 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future. (Source: Targeted Oncology)
Source: Targeted Oncology - August 24, 2018 Category: Cancer & Oncology Source Type: research

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
In conclusion, available data indicate that fulvestrant combined with agents targeting mechanisms of endocrine resistance is a promising approach. The ongoing trials identified in this review will help further inform the selection of combination treatments with fulvestrant for HR+ ABC. (Source: Targeted Oncology)
Source: Targeted Oncology - August 22, 2018 Category: Cancer & Oncology Source Type: research

Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells
AbstractBackgroundHypovitaminosis D is associated with an adverse prognosis in colon cancer patients, possibly due to the effects of the vitamin on the immune system. Antibody-dependent cell-mediated cytotoxicity (ADCC) significantly contributes to the anti-tumor effects of monoclonal antibodies, including cetuximab, an epidermal growth factor receptor (EGFR)-targeted monoclonal antibody that is frequently added to chemotherapy in the treatment of colon cancer.ObjectiveThe present study evaluates the association between vitamin D serum levels and the ability of ex vivo NK cells to support cetuximab-mediated ADCC in colon c...
Source: Targeted Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
AbstractThe intravenous CD22-directed antibody drug conjugate inotuzumab ozogamicin (Besponsa®) is approved in several countries including in the USA, EU and Japan, as monotherapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). In adults with relapsed/refractory B-cell ALL who had received one or two prior treatment regimens, inotuzumab ozogamicin was associated with significantly higher rates of complete remission (including complete remission with incomplete haematological recovery) [CR/CRi] than standard therapy in the pivotal INO-VATE ALL trial. Inotuzumab ozogamicin...
Source: Targeted Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells
AbstractBackgroundHypovitaminosis D is associated with an adverse prognosis in colon cancer patients, possibly due to the effects of the vitamin on the immune system. Antibody-dependent cell-mediated cytotoxicity (ADCC) significantly contributes to the anti-tumor effects of monoclonal antibodies, including cetuximab, an epidermal growth factor receptor (EGFR)-targeted monoclonal antibody that is frequently added to chemotherapy in the treatment of colon cancer.ObjectiveThe present study evaluates the association between vitamin D serum levels and the ability of ex vivo NK cells to support cetuximab-mediated ADCC in colon c...
Source: Targeted Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Niraparib: A Review in Ovarian Cancer
AbstractNiraparib (Zejula®), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. Approval was based on the results of the randomized, double-blind, placebo-controlled phase III NOVA trial. In NOVA, niraparib significantly prolonged progression-free survival (primary endpoint), chemotherapy-free interval and time to first subsequent therapy compared with placebo in patients with recurrent, platinum-sensitive, high grade s...
Source: Targeted Oncology - August 3, 2018 Category: Cancer & Oncology Source Type: research

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches
AbstractAdvanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent ...
Source: Targeted Oncology - August 2, 2018 Category: Cancer & Oncology Source Type: research

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab -Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
ConclusionsThis non-gemcitabine-based regimen resulted in higher response rates and better survival than what is commonly observed with therapy given at conventional dosing schedules. Low-dose continuous (metronomic therapy) cytotoxic chemotherapy combined with antiangiogenic therapy is safe and effective. (Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
ConclusionsIn this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of theEGFR-T790M –resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status. (Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study
ConclusionIn this cohort, the use of tNGS was feasible, detected frequent genomic alterations, and was used late in the disease course. Further studies and larger portfolios of targeted therapy trials are needed to maximize the benefit of tNGS in this population. (Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
AbstractImmunotherapy medications that target programmed death 1 protein (PD-1) and programmed death-ligand 1 (PD-L1), such as nivolumab, pembrolizumab, and atezolizumab, are currently used in the first- or second-line treatment of non-small cell lung cancers, among other indications. However, these agents are associated with immune-related side effects, the most common of which are endocrinopathies, colitis, hepatitis, and interstitial pneumonitis. In contrast, coronary toxicities are rarely reported and remain poorly understood. Here, we describe the case of a patient who developed an acute coronary syndrome when treated...
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
AbstractThe third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against theEGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; ...
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Niraparib: A Review in Ovarian Cancer
AbstractNiraparib (Zejula®), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. Approval was based on the results of the randomized, double-blind, placebo-controlled phase III NOVA trial. In NOVA, niraparib significantly prolonged progression-free survival (primary endpoint), chemotherapy-free interval and time to first subsequent therapy compared with placebo in patients with recurrent, platinum-sensitive, high grade s...
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma
AbstractSarcomas encompass a group of rare solid tumors responsible for approximately 1% of all cancer-related deaths in the United States each year. Subtypes include, but are not limited to, soft tissue sarcomas (STS) such as leiomyosarcoma, liposarcoma, pleomorphic sarcoma, and gastrointestinal stromal tumor (GIST). Treatment options for patients with STS vary depending on, among other factors, histological subtype. Data from a mix of phase 2 and phase 3 trials have suggested that the orally available multikinase inhibitor regorafenib may have efficacy in patients with STS who have progressed on previous lines of systemi...
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis
AbstractAbundant tumor stroma is a hallmark of pancreatic ductal adenocarcinoma (PDAC), and is suggested to play a role in the resistance of this deadly disease to systemic treatment. Despite promising results from preclinical studies, clinical trials with therapies targeting the tumor stroma and the vascular endothelial growth factor (VEGF) and its receptor VEGFR yielded conflicting results. With this systematic review and meta-analysis, we aim to summarize the existing evidence in this important field with a special focus on anti-VEGF/VEGFR therapy. A total of 24 clinical studies were included in the qualitative synthesi...
Source: Targeted Oncology - July 31, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
ConclusionsIn this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of theEGFR-T790M –resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status. (Source: Targeted Oncology)
Source: Targeted Oncology - July 23, 2018 Category: Cancer & Oncology Source Type: research

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours
AbstractReceptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling cascades, and as such are involved in a broad variety of cellular functions including differentiation, proliferation, migration, invasion, angiogenesis, and survival under physiological as well as pathological conditions. Aberrant RTK activation can lead to benign proliferative conditions as well as to various forms of cancer. Indeed, more than 70% of the known oncogene and proto-oncogene transc...
Source: Targeted Oncology - July 13, 2018 Category: Cancer & Oncology Source Type: research

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
AbstractImmunotherapy medications that target programmed death 1 protein (PD-1) and programmed death-ligand 1 (PD-L1), such as nivolumab, pembrolizumab, and atezolizumab, are currently used in the first- or second-line treatment of non-small cell lung cancers, among other indications. However, these agents are associated with immune-related side effects, the most common of which are endocrinopathies, colitis, hepatitis, and interstitial pneumonitis. In contrast, coronary toxicities are rarely reported and remain poorly understood. Here, we describe the case of a patient who developed an acute coronary syndrome when treated...
Source: Targeted Oncology - July 13, 2018 Category: Cancer & Oncology Source Type: research

Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo
ConclusionsFolic acid-conjugated 17-AAG magnetic thermosensitive liposomes in combination with an alternating magnetic field for heating can achieve a synergistic anti-tumor effect of chemotherapy and heat treatment, potentially offering a new method for ovarian cancer treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - July 10, 2018 Category: Cancer & Oncology Source Type: research

Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study
ConclusionIn this cohort, the use of tNGS was feasible, detected frequent genomic alterations, and was used late in the disease course. Further studies and larger portfolios of targeted therapy trials are needed to maximize the benefit of tNGS in this population. (Source: Targeted Oncology)
Source: Targeted Oncology - July 4, 2018 Category: Cancer & Oncology Source Type: research

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma
AbstractSarcomas encompass a group of rare solid tumors responsible for approximately 1% of all cancer-related deaths in the United States each year. Subtypes include, but are not limited to, soft tissue sarcomas (STS) such as leiomyosarcoma, liposarcoma, pleomorphic sarcoma, and gastrointestinal stromal tumor (GIST). Treatment options for patients with STS vary depending on, among other factors, histological subtype. Data from a mix of phase 2 and phase 3 trials have suggested that the orally available multikinase inhibitor regorafenib may have efficacy in patients with STS who have progressed on previous lines of systemi...
Source: Targeted Oncology - June 21, 2018 Category: Cancer & Oncology Source Type: research

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
AbstractThe third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against theEGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; ...
Source: Targeted Oncology - June 16, 2018 Category: Cancer & Oncology Source Type: research

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
AbstractBackgroundThe variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking.ObjectiveThe MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III –IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab.Patients and MethodsOf the 375 patie...
Source: Targeted Oncology - June 14, 2018 Category: Cancer & Oncology Source Type: research

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab -Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
ConclusionsThis non-gemcitabine-based regimen resulted in higher response rates and better survival than what is commonly observed with therapy given at conventional dosing schedules. Low-dose continuous (metronomic therapy) cytotoxic chemotherapy combined with antiangiogenic therapy is safe and effective. (Source: Targeted Oncology)
Source: Targeted Oncology - June 7, 2018 Category: Cancer & Oncology Source Type: research

Avelumab: A Review in Metastatic Merkel Cell Carcinoma
In conclusion, currently available data suggest that avelumab present s a clinically beneficial new treatment option for metastatic MCC, a rare but aggressive cancer associated with a poor prognosis. (Source: Targeted Oncology)
Source: Targeted Oncology - May 24, 2018 Category: Cancer & Oncology Source Type: research